HBK Sorce Advisory LLC Sells 4,661 Shares of Johnson & Johnson $JNJ

HBK Sorce Advisory LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,083 shares of the company’s stock after selling 4,661 shares during the quarter. HBK Sorce Advisory LLC’s holdings in Johnson & Johnson were worth $9,192,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Clayton Financial Group LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $28,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson during the second quarter valued at approximately $27,000. Semmax Financial Advisors Inc. raised its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares in the last quarter. GFG Capital LLC purchased a new stake in Johnson & Johnson during the second quarter worth $35,000. Finally, 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at $48,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.1%

Shares of Johnson & Johnson stock opened at $207.54 on Monday. The firm’s 50 day simple moving average is $199.67 and its two-hundred day simple moving average is $181.22. The firm has a market capitalization of $500.02 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research note on Monday, October 20th. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Stifel Nicolaus boosted their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Finally, Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $210.25.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.